Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1

Jessica Kalra(University of British Columbia), Marcel B. Bally(BC Cancer Agency)

Oncogene

September 13, 2010

10.1038/onc.2010.366

Cited by 49

Related Papers

Induction of Autophagy Is an Early Response to Gefitinib and a Potential Therapeutic Target in Breast Cancer

|PLoS ONE|2013|101

QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model

|Breast Cancer Research|2009|73

Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent

|International Journal of Nanomedicine|2017|65

The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity

|BMC Cancer|2011|28

Combined RNAi-Mediated Suppression of Rictor and EGFR Resulted in Complete Tumor Regression in an Orthotopic Glioblastoma Tumor Model

|PLoS ONE|2013|28